Pangea Biomed

What Pangea Biomed does

Pangea Biomed is an Israel-based precision oncology company founded in 2018 that develops the ENLIGHT proprietary tumor intelligence platform for predicting patient response to cancer therapies. Rather than relying on actionable genomic mutations alone, ENLIGHT infers "gene social networks" of functional genetic interactions from multi-omics data (expression, epigenetics, proteomics) and ranks dozens of treatment options per patient with an ENLIGHT Matching Score. The company commercializes this capability through two products: ENLIGHT-NGS, an RNA-based drug matching test run on standard FFPE pathology samples and commercially available in several countries; and ENLIGHT-DP, which applies the DeepPT deep learning framework to predict tumor mRNA expression directly from H&E-stained histopathology slides, slated for commercial availability in 2025. DeepPT, validated across 16 TCGA cohorts, enables treatment matching without requiring NGS sequencing, materially lowering access barriers.

The company monetizes through two channels: (i) per-test or commercial availability of ENLIGHT-NGS for oncologists ordering treatment matching, and (ii) platform licensing or collaboration agreements with biopharmaceutical companies for drug discovery, target identification, and clinical trial design, with a dedicated Chief, Pharma Alliances executive leading the effort. Pangea Biomed's customer base spans biopharma companies (primary segment), hospitals and cancer centers (primary), and academic research institutions (secondary), with named engagements including OHSU Knight Cancer Institute, Hadassah University Hospital, Sheba Medical Center, the LiquidBX Consortium, and the US National Cancer Institute. The company has raised $12M in total seed funding led by NFX, is actively participating in major oncology conferences (ASCO, AACR, BIO), and has been recognized on Fast Company's 2024 Next Big Things in Tech list.

Name

Pangea Biomed

Legal name

Pangea Biomed

Website

https://pangeabiomed.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Pangea Biomed is an Israel-based precision oncology company whose ENLIGHT platform uses multi-omics and machine learning to predict patient cancer treatment response and rank therapeutic options. It sells ENLIGHT-NGS RNA-based drug matching tests and is launching ENLIGHT-DP for H&E slide-based predictions, serving hospitals, cancer centers, and biopharmaceutical partners.

Ownership category

akta.pro rank

Product category

Precision Oncology Software & Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro industry

PRIMARYHLAGAJAD

Bioinformatics & Multi-omics Analysis Software

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAGAJAO

AI/ML Platforms for Drug Discovery & Experiment Optimization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAIALAF

Translational Medicine & Biomarkers

Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

• Precision oncology
• RNA-based diagnostics
• Cancer treatment matching
• Digital pathology AI
• Genetic interaction analysis

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. ENLIGHT-NGS Commercial Testing: RNA-based drug matching tests commercially available in several countries. Physicians order tests derived from FFPE pathology samples to receive actionable treatment recommendations with ENLIGHT Matching Scores.
2. Platform Licensing to Pharma: Biotech/pharma companies and research groups use the ENLIGHT platform for drug development and treatment nomination, likely through licensing agreements.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Pangea Biomed develops and sells the ENLIGHT proprietary tumor intelligence platform, which analyzes molecular context (expression, epigenetics, proteomics) and genetic interactions to predict cancer treatment response. The company delivers two commercial products: ENLIGHT-NGS, an RNA-based drug matching test from FFPE sequencing samples, and ENLIGHT-DP (powered by DeepPT), a treatment matching test derived directly from H&E histopathology slides without requiring NGS. Both products assign ENLIGHT Matching Scores to dozens of treatment options per patient.

Product overview

Pangea Biomed offers the ENLIGHT proprietary tumor intelligence platform for precision oncology, consisting of two main commercial products: ENLIGHT-NGS (RNA-based drug matching from FFPE sequencing samples) and ENLIGHT-DP (treatment matching directly from H&E histopathology slides). Both products are powered by the ENLIGHT platform which uses genetic interaction analysis and machine learning to screen and rank dozens of treatment options per patient, assigning ENLIGHT Matching Scores. The DeepPT deep learning component enables transcriptomics prediction from standard pathology slides, extending accessibility of precision oncology.

Differentiator

Problem solved

Functional benefit

Brands

• ENLIGHT: Proprietary tumor intelligence platform that enables deeper understanding of how tumors respond to therapy by examining molecular context including expression abnormalities, epigenetics, and proteomics.
• ENLIGHT-NGS
• ENLIGHT-DP
• DeepPT

Products and services

• ENLIGHT-NGS ENLIGHT-NGS is an RNA-based drug matching analysis test driven by deep transcriptomic analysis. Based on sequencing derived from standard FFPE (Formalin Fixed, Paraffin Embedded) pathology samples, it delivers an actionable report helping physicians make informed treatment decisions. It screens dozens of treatment options, assigns each an ENLIGHT Matching Score, and categorizes matches by level of evidence. Commercially available in several countries with expansion planned.
• ENLIGHT-DP ENLIGHT-DP is a treatment matching analysis solution that works directly from H&E slides using DeepPT, Pangea's digital pathology deep learning platform combined with ENLIGHT. It computes ENLIGHT Matching Scores for dozens of drugs from standard H&E-stained pathology slides without the need to wait for NGS results. Scheduled for commercial availability in 2025.
• ENLIGHT Platform (Tumor Intelligence Platform) The ENLIGHT platform is Pangea's proprietary tumor intelligence platform consisting of two engines: the Inference Engine, which processes multiple big-data repositories to infer Genetic Interactions and produce GI Maps, and the Predictive Engine, which combines GI Maps with drug, pathway, and patient-specific multi-omics data to derive personalized treatment response predictions. It is offered to biopharmaceutical and research partners for drug discovery, indication expansion, and clinical trial design.

Quantifiable outcome

• 80% predictive success rate across 35 published targeted and immunotherapy clinical trials from 10 different cancer types
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Six partnerships are on record, tiered core and minor.

• OHSU Knight Cancer InstitutecoreStrategic or Co-development Partner · 24 October 2024Pilot collaboration to improve cancer therapy precision using the ENLIGHT platform. Joint effort to validate and deploy AI-powered treatment matching at a major US cancer center.
• Dr. Kenneth AldapeminorOthers · 2 October 2024Dr. Kenneth Aldape from the US National Cancer Institute joined Pangea Biomed's Scientific Advisory Board, bringing expertise in molecular neuropathology and tumor diagnostics.
• LiquidBX ConsortiumminorStrategic or Co-development Partner · 5 September 2024Pangea joined the second phase of the LiquidBX consortium to improve cancer detection and treatment response prediction, collaborating with multiple industry partners.
• Hadassah University Hospital and Ultima GenomicscoreStrategic or Co-development Partner · 7 August 2024Strategic collaboration with Sharett Institute of Oncology and Hadassah Cancer Research Institute along with Ultima Genomics for solid tumor cancer treatment research, combining ENLIGHT with Ultima's genomic sequencing capabilities.
• Sheba Medical CentercoreStrategic or Co-development PartnerOngoing collaboration with Sheba Medical Center for clinical research, including studies on PARP inhibitor response in BRCA-associated pancreatic cancer and other precision oncology applications.
• Research Institutions (Partner Logos)minorStrategic or Co-development PartnerPangea engages with some of the most advanced and innovative medical institutions and research labs. The company maintains multiple institutional partnerships for clinical validation and research collaboration.

Scale indicators3 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Personalis: Cancer genomics company with a tumor-only DNA + whole-transcriptome (RNA) assay and a pharma biomarker/biopharma CDx business. Highly comparable to Pangea on the RNA-based response prediction approach and biopharma customer segment.
• Tempus Labs: AI-driven precision medicine company offering multi-omics profiling (DNA/RNA) and treatment recommendation reports for oncologists. Closest direct competitor to ENLIGHT-NGS, with similar model of combining sequencing + ML for therapy matching, and a parallel pharma services business.
• Caris Life Sciences: Offers molecular profiling (DNA, RNA, protein) plus an AI platform (MI Profile, MI Cancer Seek) that pairs with treatment recommendations. Directly comparable in the molecular treatment-matching category with a substantial pharma ADX/biomarker business.
• Strata Oncology: Precision oncology platform delivering molecular profiling reports to oncologists and running a large prospective observational trial (Strata Sentinel). Comparable in the tumor profiling + treatment matching category with similar enterprise health-system GTM motion.

Emerging players

• PathAI: AI/digital pathology company applying deep learning to H&E slides, including a biomarker/companion diagnostics business. Closest analogue to Pangea's DeepPT (image-to-transcriptomics) approach and an obvious strategic or competitive counterparty in the H&E-based treatment matching space.
• Owkin: AI-for-drug-discovery and diagnostics company applying ML to multi-modal patient data for biomarker and target discovery, with a meaningful pharma services business. Comparable on the AI/ML + multi-omics + pharma customer model, though more drug-discovery-weighted.
• Predicine: Liquid biopsy + AI company offering genomics and transcriptomics-based tests for therapy selection and clinical trial biomarker work. Comparable technology stack and customer base but smaller and earlier-stage than Pangea's institutional peers.

Broad incumbents

• NeoGenomics: Established oncology-focused clinical lab services company with a growing proprietary profiling and pharma services business (e.g., RaDaR, NGS panels). Comparable in hospital/cancer-center oncology testing GTM, but much broader and more diversified.
• Guardant Health: Liquid biopsy leader with Guardant360 CDx and a growing multi-omics + therapy selection franchise. Comparable in oncology treatment selection, though dominated by liquid biopsy rather than tissue-based RNA; offers a useful scale and reimbursement benchmark.
• Foundation Medicine: Roche-owned leader in comprehensive genomic profiling for oncology treatment selection. Directly comparable as a molecular profiling + clinical reporting service for oncologists, but operates at vastly larger scale and as part of a global diagnostics platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/PangeaBiomed
• YouTubeyoutube.com/channel/UC0tgNPLez863ZMHRGrs-HyQ
• LinkedInlinkedin.com/company/pangea-biomed

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pangea Biomed